474 Results (Page 1 of 19)
Egypt Markets Research Reports
Egypt Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
Egypt's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $51 Mn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $99 Mn in 2030. One of the main reasons propelling the growth of this market is government initiatives, Aging population. The market is segmented by drug class and distribution channel. Some key players in this market are EIPICO, Pharco, Amoun, Memphis Pharmaceutical, Eva Pharma, Almirall, Astellas Pharma, American Hospital of Paris, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, and others.
Egypt Clinical Trials Support Service Market Analysis
This report presents a strategic analysis of the Egypt Clinical Trials Support Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Egypt Clinical Trials Support Service Market, offering unmatched value, accuracy and expert insights.
Egypt Retail Pharmacy Market Analysis
This report presents a strategic analysis of the Egypt Retail Pharmacy Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Egypt Retail Pharmacy Market, offering unmatched value, accuracy and expert insights.
Egypt Growth Hormone Deficiency Clinical Trials Market Analysis
This report presents a strategic analysis of the Egypt Growth Hormone Deficiency Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Egypt Growth Hormone Deficiency Clinical Trials Market, offering unmatched value, accuracy, and expert insights.
Egypt Hemodialysis Vascular Grafts Market Analysis
Egypt Hemodialysis Vascular Grafts Market was valued at $590 Mn in 2023 and is predicted to grow at a CAGR of 6.6% from 2023 to 2030, to $920 Mn by 2030. The key drivers of this industry include the rising prevalence of chronic kidney disease, the growing diabetic population, government initiatives, and technological advancements. The industry is primarily dominated by W. L. Gore, C. R. Bard, Vascudyne, and LeMaitre among others.
Egypt Contact Lenses Market Analysis
Egypt Contact Lenses Market was valued at $47.99 Mn in 2023 and is predicted to grow at a CAGR of 10.4% from 2023 to 2030, $95.93 Mn by 2030. The key drivers of this industry include the rising vision problems, growing disposable income, and technological advancement. The industry is primarily dominated by Bausch and Lomb, CooperVision, Alcon Vision, and Essilor among others.
Egypt Primary Hyperoxaluria (PH) Therapeutics Market Analysis
Egypt Primary Hyperoxaluria (PH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors propelling the growth of the hyperoxaluria drug market is the rise in the number of persons with the condition worldwide. The regulatory body's extension of special designations and rising consumer demand for medications including thiazide diuretics, calcium oxalate urinary inhibitors, and others to address a variety of health issues both contribute to the market's quick growth. Major global players in Primary Hyperoxaluria (PH) Therapeutics Market are Allena Pharmaceuticals, Inc., Intellia Therapeutics, Inc., OxThera, Dicerna Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Inc., Pfizer Inc., and Sanofi.
Egypt Artificial Intelligence (AI) in Diagnostics Market Analysis
Egypt's Artificial Intelligence (AI) in the diagnostics market is projected to grow from $2.8 Mn in 2022 to $33.75 Mn by 2030, registering a CAGR of 36.5% during the forecast period of 2022-2030. The market will be driven by the country's attempts to improve ’s entire healthcare system, as well as the significant demand for modern diagnostic solutions. The market is segmented by component & by diagnosis. Some of the major players include IBM Watson Health, Siemens Healthineers & Lunit Inc.
Egypt Lipid Disorder Therapeutics Market Analysis
The Egypt Lipid Disorder Therapeutics Market was valued at $65.7 Mn in 2023 and is predicted to grow at a CAGR of 13.86% from 2023 to 2030, to $162.9 Mn by 2030. Egypt's Lipid Disorder Therapeutics Market is growing due to the Rising Prevalence of Non-Communicable Diseases, Growing Awareness and Focus on Chronic Disease Management, and Rising Demand for Digitalized Healthcare Services. The industry is primarily dominated by players such as Sanofi, Sun Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Viatris, AstraZeneca PLC, and Dr. Reddys Laboratories Ltd.
Egypt Kidney Cancer Therapeutics Market Analysis
The Egypt Kidney Cancer Therapeutics Market was valued at $17.61 Mn in 2023 and is predicted to grow at a CAGR of 6.36% from 2023 to 2030, to $27.12 Mn by 2030. The key drivers of this industry include the rising incidence of kidney cancer, advancements in treatment options, and the growing aging population. The industry is primarily dominated by players such as AstraZeneca, Pfizer, Novartis, Bayer, Roche, Bristol Myers Squibb, Merck, Abbott, Amgen, and Takeda Pharmaceutical.
Egypt Virtual Clinical Trials Market Analysis
This report presents a strategic analysis of the Egypt Virtual Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Egypt Virtual Clinical Trials Market, offering unmatched value, accuracy and expert insights.
Egypt Dental Consumables Market Analysis
The Egypt Dental Consumables Market was valued at $94.6 Mn in 2023 and is projected to grow at a CAGR of 9.5% from 2023 to 2023, to $178.6 Mn by 2030. The key drivers of this industry growing dental care needs, technological advancements, expanding dental infrastructure, increasing disposable incomes, public health initiatives, dental toursm, rising consumption of sugary and starchy foods, rise in unhealthy eating habits due to rising urbanization, changing living standards. The industry is primarily dominated by players such as Marico Egypt, Amoun Pharmaceutical Company, Eva Pharma, Siwa Holding, Pharco Pharmaceuticals, Dentsply Sirona, Danaher, Align Technology, among others.
Egypt Dental Caries Detectors Market Analysis
The Egypt Dental Caries Detectors Market was valued at $0.6 Mn in 2023 and is predicted to grow at a CAGR of 10.4% from 2023 to 2030, to $1.3 Mn by 2030. Egypt Dental Caries Detectors Market is growing due to the prevalence of dental caries, Rising awareness, and Government Initiatives and Funding. The market is primarily dominated by players such as Dr. Fresh LLC, Dentaid Lion Corporation, Sunstar Suisse, Sirona Dental Systems, Dentsply Sirona, KaVo Kerr, Ivoclar Vivadent, Planmeca Oy, Adec Technologies, 3M ESPE, Morita Corporation, Woodpecker Medical Instruments Co., Softdent.
Egypt Clinical Nutrition for Diabetes Care Market Analysis
The Egypt Clinical Nutrition for Diabetes Care Market was valued at $6.02 Mn in 2023 and is predicted to grow at a CAGR of 6.28% from 2023 to 2030, to $9.22 Mn by 2030. The key drivers of this industry include increasing the prevalence of diabetes, advancements in nutritional science, and initiatives for diabetes management. The key players in the industry are Nestle Health Science, Sanofi, Pharco Pharmaceuticals, and Novo Nordisk among others.
Egypt Pharmacy Automation Device Market Analysis
The Egypt Pharmacy Automation Device Market was valued at $15.4 Mn in 2023 and is predicted to grow at a CAGR of 11.4% from 2023 to 2030, to $32.8 Mn by 2030. Egypt Pharmacy Automation Device Market is growing due to Adoption of Electronic Health Records, Growing Need to Minimize Medication Errors, Rising Demand for Pharmaceuticals. The market is primarily dominated by players such as Becton Dickinson and Co, Capsa Solutions LLC, Omnicell Inc, Oracle Corp, Veradigm LLC, Swisslog Healthcare AG, McKesson Corporation; Pearson Medical Technologies.
Egypt Cardiac Pacemakers Market Analysis
The Egypt Cardiac Pacemakers Market was valued at $11.33 Mn in 2023 and is predicted to grow at a CAGR of 4.7% from 2023 to 2030, to $15.63 Mn by 2030. The key drivers of this industry include increasing incidence, aging population, and healthcare investment. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
Egypt Hepatorenal Syndrome Therapeutics Market Analysis
Egypt Hepatorenal Syndrome Therapeutics (HRS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. People with cirrhosis or acute liver failure who develop kidney impairment are said to have hepatorenal syndrome (HRS), a serious consequence of advanced liver disease. Renal function improvement and halting further decline are the main objectives of treatment for hepatorenal syndrome. The market for HRS Therapeutics is being driven by an increase in the number of patients with liver illnesses, ongoing medical technology breakthroughs, government efforts, and partnerships and collaborations amongst pharmaceutical companies. Ferring Pharmaceuticals, Hospira, Pfizer, Sandoz, Novartis, Grifols, CSL Behring, Octa pharma, and Baxalta are major international participants in the market for treatments for hepatocellular syndrome.
Egypt Guillain-Barre Syndrome (GBS) Therapeutics Market Analysis
Egypt Guillain-Barre Syndrome (GBS) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Guillain Barre Syndrome is a rare autoimmune disorder in which persons immune system attacks nervous system. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.
Egypt Glioblastoma Multiforme Therapeutics Market Analysis
Egypt Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The most aggressive primary brain tumour is glioblastoma, also known as glioblastoma multiforme (GBM), which makes up for 15% of all intracranial neoplasms and 49% of malignant brain tumours. GBM is more common and has a worse prognosis as people age. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Consequently, the GBM market has drivers. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Global The following companies are significant players in the market: Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc., Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. (Boston Biomedical, Inc.)
Egypt Frontotemporal Disorders Therapeutics Market Analysis
Egypt Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neurons in the frontal and temporal lobes of the brain are damaged in frontotemporal diseases (FTD), also known as frontotemporal dementia. As the patient population for FTD is growing, non-profit organisations, illness advocacy groups, and private organisations are currently concentrating on supporting treatment research. A major driver of the frontotemporal disorders treatment market growth is predicted to be the rising life expectancy rate, which is also expected to contribute to the increasing prevalence of neurological diseases among the older population. Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., and Teva Pharmaceuticals USA, Inc. are just a few of the well-known worldwide and local businesses that are examined in the competitive landscape.
Egypt Fibrodysplasia Ossificans Progressiva (FOP) Therapeutics Market Analysis
Egypt Fibrodysplasia Ossificans Progressiva Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An estimated 1.36 per Mn persons are believed to have the ultra-rare condition fibrodysplasia osseous progressiva, which affects about 900 people worldwide. The market for Fibrodysplasia Ossificans Progressiva Drugs is expanding as a result of growing incidence and prevalence of fibrodysplasia ossificans progressiva, increase in the number of R&D activities, increase in Partnerships and Collaborations between market players. Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Novartis are the top key market players operating in the global Fibrodysplasia Ossificans Progressiva Therapeutics Market.
Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis
Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A genetic condition known as Duchenne muscular dystrophy (DMD) is characterised by advancing muscle weakness and degeneration as a result of changes to a protein called dystrophin, which aids in maintaining healthy muscle cells. The market is expanding as a result of favourable government initiatives that provide appropriate reimbursement policies and promote target-specific treatments. Rapid urbanisation, better medical infrastructure, the emergence of product premiumization, and rising disposable incomes among the general populace are a few other drivers generating profitable growth potential in the industry. Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals, and many more are Global companies in the DMD Therapeutics market.
Egypt Dilated Cardiomyopathy Therapeutics Market Analysis
Egypt Dilated Cardiomyopathy Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The phrase "dilated cardiomyopathy" refers to conditions that affect the heart muscle and is regarded as a deadly cardiac condition. Reduced myocardial contractility and left and right ventricular dilatation are usually its defining characteristics. The potential driving force behind the DCM Therapeutics Market has been the rise in diagnostic alterations and symptom awareness, as well as declining dietary and lifestyle choices that have led to an increase in the occurrence of disease. The government is sponsoring research and development (R&D) projects to encourage scientists and pharmaceutical firms to create novel treatments. Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vericel Corporation, and many others are key players in the market for cystic fibrosis (CF) therapeutics.
Egypt Cystic Fibrosis (CF) Therapeutics Market Analysis
Egypt Cystic Fibrosis (CF) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Cystic fibrosis (abbreviated CF) is a genetic disorder that causes mucus to build up in certain organs of the body, particularly the lungs and pancreas, resulting in breathing problems, respiratory infections and faulty digestion. The increasing prevalence of Cystic Fibrosis (CF) coupled with the rising treatment rate is one of the key factors anticipated to propel the demand for cystic fibrosis therapeutics over the forecast period. The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.
Egypt Clinical Nutrition for Cancer Care Market Analysis
The Egypt Clinical Nutrition for Cancer Care Market was valued at $15.8 Mn in 2023 and is predicted to grow at a CAGR of 6.54% from 2023 to 2030, to $24.6 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, improved healthcare infrastructure, and rising disposable incomes. The prominent players of the Egypt Clinical Nutrition for Cancer Care Market are Fresenius Kabi, Otsuka, and Egyptian Society of Nutrition and Food Science (ESNFS), among others.